Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates

Core Insights - Armata Pharmaceuticals reported a quarterly loss of $0.42 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.15 per share a year ago [1] - The company posted revenues of $1.16 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 16.01%, and down from $2.97 million year-over-year [2] - The stock has increased approximately 264.9% since the beginning of the year, significantly outperforming the S&P 500's gain of 16.4% [3] Financial Performance - The company has surpassed consensus EPS estimates three times over the last four quarters [1] - The current consensus EPS estimate for the upcoming quarter is -$0.41 on revenues of $1.47 million, and for the current fiscal year, it is -$1.46 on revenues of $5.5 million [7] Market Outlook - The earnings outlook and management's commentary during the earnings call will be crucial for the stock's immediate price movement [3][4] - The Zacks Rank for Armata Pharmaceuticals is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry is currently in the top 34% of over 250 Zacks industries, suggesting a favorable environment for stocks within this sector [8] - Another company in the same industry, Fortress Biotech, is expected to report a quarterly loss of $0.43 per share, with revenues projected to be $23.68 million, reflecting a year-over-year increase of 61.9% [9]